JP2025517683A - デングウイルス感染症の治療及び／又は予防 - Google Patents

デングウイルス感染症の治療及び／又は予防 Download PDF

Info

Publication number
JP2025517683A
JP2025517683A JP2024566556A JP2024566556A JP2025517683A JP 2025517683 A JP2025517683 A JP 2025517683A JP 2024566556 A JP2024566556 A JP 2024566556A JP 2024566556 A JP2024566556 A JP 2024566556A JP 2025517683 A JP2025517683 A JP 2025517683A
Authority
JP
Japan
Prior art keywords
days
compound
weight
kcal
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517683A5 (enExample
Inventor
アカート，オリバー
バゲット，トリスタン
バルマン，クレア
ゴーイバーツ，ネレ
エレーラ－タラセナ，ギリェルモ
ハンジェンス，ディンフィー
ラスチャート，フレヤ
シュロエン，ブラム
サマーズ，イヴァン
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2025517683A publication Critical patent/JP2025517683A/ja
Publication of JP2025517683A5 publication Critical patent/JP2025517683A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024566556A 2022-05-12 2023-05-01 デングウイルス感染症の治療及び／又は予防 Pending JP2025517683A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341074P 2022-05-12 2022-05-12
US63/341,074 2022-05-12
PCT/IB2023/054527 WO2023218285A1 (en) 2022-05-12 2023-05-01 Treatment or prevention of dengue viral infection

Publications (2)

Publication Number Publication Date
JP2025517683A true JP2025517683A (ja) 2025-06-10
JP2025517683A5 JP2025517683A5 (enExample) 2026-05-13

Family

ID=86558745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566556A Pending JP2025517683A (ja) 2022-05-12 2023-05-01 デングウイルス感染症の治療及び／又は予防

Country Status (8)

Country Link
US (1) US20250281457A1 (enExample)
EP (1) EP4522163A1 (enExample)
JP (1) JP2025517683A (enExample)
CN (1) CN119173261A (enExample)
AU (1) AU2023269343A1 (enExample)
CA (1) CA3257185A1 (enExample)
TW (1) TW202400144A (enExample)
WO (1) WO2023218285A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN114980884A (zh) * 2019-11-15 2022-08-30 杨森制药公司 登革热疾病的治疗和预防

Also Published As

Publication number Publication date
CA3257185A1 (en) 2023-11-16
US20250281457A1 (en) 2025-09-11
AU2023269343A1 (en) 2025-01-02
TW202400144A (zh) 2024-01-01
CN119173261A (zh) 2024-12-20
EP4522163A1 (en) 2025-03-19
WO2023218285A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US20030147950A1 (en) Modified release tamsulosin tablets
WO2022036506A1 (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
EP4240331B1 (en) Solid formulation
KR100846945B1 (ko) 파라세타몰을 포함하는 연하 정제
WO2005051350A2 (en) Water dispersible tablet
CN110917157B (zh) 含炔基化合物的药物组合物、其制备方法及应用
US20070160664A1 (en) Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent
US20250281457A1 (en) Treatment or prevention of dengue viral infection
US20170368049A1 (en) Composite capsules comprising raloxifene, and vitamin d or its derivatives
CN118284415B (zh) 一种达罗他胺药物组合物及其制备方法和用途
US20070053975A1 (en) Ramipril formulation
WO2020089761A1 (en) Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
HK40120143A (zh) 登革热病毒感染的治疗和/或预防
KR20240141090A (ko) 용출률이 개선된 닌테다닙을 포함하는 약제학적 조성물
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
TWI923631B (zh) 固體配製物
CN103948551A (zh) 一种多潘立酮控释片及其制备方法
WO2012148225A2 (en) Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same
KR20200015758A (ko) 제약 조성물
HK40099185A (zh) 固体制剂
US20210369615A1 (en) Solid oral formulations of amphotericin b
RU2020143156A (ru) Фармацевтическая комбинация, композиция и комбинированный состав, содержащий активатор глюкокиназы и бигуанидное гипогликемическое лекарственное средство, а также способ их приготовления и их применение
RU2020143136A (ru) Фармацевтическая комбинация, композиция и комбинированный состав, содержащие активатор глюкокиназы и активатор рецептора ppar, и способ их приготовления и их применение
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260430